Pathology (neoplasia 5/molecular basis)

Card Set Information

Author:
amirh899
ID:
240988
Filename:
Pathology (neoplasia 5/molecular basis)
Updated:
2013-10-16 14:58:03
Tags:
Pathology neoplasia molecular basis
Folders:

Description:
Pathology (neoplasia 5/molecular basis)
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user amirh899 on FreezingBlue Flashcards. What would you like to do?


  1. Why do most normal human cells have a capacity of 60 to 70 doublings? and after this, the cells lose their ability to divide and become senescent
    • This phenomenon has been ascribed to progressive shortening of telomeres at the ends of chromosomes.
    • Indeed, short telomeres seem to be recognized by the DNA-repair machinery as double-stranded DNA breaks, and this leads to cell cycle arrest mediated by p53 and RB
  2. What does happens to cell that has shortened telomere and at the same time inactivating mutation of P53 or RB?
    • In cells in which the checkpoints are disabled by p53 or RB1 mutations, the nonhomologous end-joining pathway is activated as a last-ditch effort to save the cell, joining the shortened ends of two chromosomes.
    • This inappropriately activated repair system results in dicentric chromosomes that are pulled apart at anaphase, resulting in new double-stranded DNA breaks.
    • The resulting genomic instability from the repeated bridge-fusion-breakage cycles eventually produces mitotic catastrophe, characterized by massive cell death
  3. To grow indefinitely a tumor must have which features?
    • Loss of growth restraints is not enough.
    • Tumor cells must also develop ways to avoid both cellular senescence and mitotic catastrophe
  4. How can cells with telomere shortening avoid death?
    • If during crisis a cell manages to reactivate telomerase, the bridge-fusion-breakage cycles cease and the cell is able to avoid death.
    • However, during the period of genomic instability that precedes telomerase activation, numerous mutations could accumulate, helping the cell march toward malignancy
  5. ......................................... may explain the complex karyotypes frequently seen in human carcinomas
    Passage through a period of genomic instability
  6. True or False: telomere maintenance is seen in all types of cancers
    True
  7. Most common mechanism for telomere maintenance is ......................................
    up-regulation of the enzyme telomerase
  8. solid tumors cannot enlarge beyond 1 to 2 mm in diameter unless they are ................
    vascularized
  9. What is the importance of new vessels for tumors?
    • Cancer cells can stimulate neo-angiogenesis, during which new vessels sprout from previously existing capillaries, or, in some cases, vasculogenesis, in which endothelial cells are recruited from the bone marrow.
    • Tumor vasculature is abnormal, however. The vessels are leaky and dilated, and have a haphazard pattern of connection.
    • Neovascularization has a dual effect on tumor growth: perfusion supplies needed nutrients and oxygen, and newly formed endothelial cells stimulate the growth of adjacent tumor cells by secreting growth factors, such as insulin-like growth factors (IGFs), PDGF, and granulocyte-macrophage colony-stimulating factor.
    • Angiogenesis is required not only for continued tumor growth but also for access to the vasculature and hence for metastasis
    • Angiogenesis is thus a necessary biologic correlate of malignancy
  10. tumor angiogenesis is controlled by .....................................
    the balance between angiogenesis promoters and inhibitors
  11. True or False: Early in their growth, most human tumors do not induce angiogenesis
    True
  12. The molecular basis of the angiogenic switch involves ................................................... ............................................................ .......................................................... .............................................................. .....................
    increased production of angiogenic factors and/or loss of angiogenic inhibitors. These factors may be produced directly by the tumor cells themselves or by inflammatory cells (e.g., macrophages) or other stromal cells associated with the tumors
  13. How can proteases promote angiogenesis?
    • Proteases, either elaborated by the tumor cells directly or from stromal cells in response to the tumor, are also involved in regulating the balance between angiogenic and anti-angiogenic factors.
    • Many proteases can release the proangiogenic basic fibroblast growth factors (bFGF) stored in the ECM; conversely, three potent angiogenesis inhibitors—angiostatin, endostatin, and vasculostatinare produced by proteolytic cleavage of plasminogen, collagen, and transthyretin
  14. How can hypoxia contribute to angiogenesis?
    • Relative lack of oxygen stimulates HIF1α, an oxygen-sensitive transcription factor, which then activates transcription of a variety of pro-angiogenic cytokines, such as VEGF and bFGF.
    • These factors create an angiogenic gradient that stimulates the proliferation of endothelial cells and guides the growth of new vessels toward the tumor.
    • VEGF also increases the expression of ligands that activate the Notch signaling pathway, which plays a crucial role in regulating the branching and density of the new vessels
  15. How can other genes affect angiogenesis?
    • For example, in normal cells, p53 can stimulate expression of anti-angiogenic molecules such as thrombospondin-1, and repress expression of pro-angiogenic molecules such as VEGF.
    • Thus, loss of p53 in tumor cells not only removes the cell cycle checkpoints listed above but also provides a more permissive environment for angiogenesis.
    • The transcription of VEGF is also influenced by signals from the RAS-MAP kinase pathway, and mutations of RAS or MYC up-regulate the production of VEGF
  16. Which angiogenic factors are widely expressed in many tumors?
    bFGF and VEGF
  17. How can angiogenesis be inhibited in tumors?
    • anti-VEGF monoclonal antibody, bevacizumab,
    • antibodies that inhibit Notch activation
  18. What are the steps of metastatic cascade?
    • (1) invasion of the extracellular matrix (ECM);
    • (2) vascular dissemination, homing of tumor cells, and colonization
  19. To metastasize A carcinoma must first breach the ....................
    underlying basement membrane
  20. What are the steps of invasion of ECM?
    • Changes (“loosening up”) of tumor cell-cell interactions  
    • Degradation of ECM  
    • Attachment to novel ECM components  
    • Migration of tumor cells
  21. How does Dissociation of cells from one another occur?
    • Often the result of alterations in intercellular adhesion molecules.
    • Cell-cell interactions are mediated by the cadherin family of transmembrane glycoproteins.
    • E-cadherins mediate homotypic adhesions in epithelial tissue, thus serving to keep the epithelial cells together and to relay signals between the cells; intracellularly the E-cadherins are connected to β-catenin and the actin cytoskeleton. 
    • In several epithelial tumors, including adenocarcinomas of the colon and breast, there is a down-regulation of E-cadherin expression. E-cadherins are linked to the cytoskeleton by the catenins, proteins that lie under the plasma membrane. The normal function of E-cadherin is dependent on its linkage to catenins. In some tumors E-cadherin is normal, but its expression is reduced because of mutations in the gene for α catenin
  22. How do tumor accomplish local degradation of the basement membrane and interstitial connective tissue?
    • Tumor cells may either secrete proteolytic enzymes themselves or induce stromal cells (e.g., fibroblasts and inflammatory cells) to elaborate proteases.
    • Many different families of proteases, such as matrix metalloproteinases (MMPs), cathepsin D, and urokinase plasminogen activator, have been implicated in tumor cell invasion.
    • MMPs regulate tumor invasion not only by remodeling insoluble components of the basement membrane and interstitial matrix but also by releasing ECM-sequestered growth factors.
    • Indeed, cleavage products of collagen and proteoglycans also have chemotactic, angiogenic, and growth-promoting effects.
    • For example, MMP9 is a gelatinase that cleaves type IV collagen of the epithelial and vascular basement membrane and also stimulates release of VEGF from ECM-sequestered pools
    • Concurrently, the concentrations of metalloproteinase inhibitors are reduced so that the balance is tilted greatly toward tissue degradation.
  23. Benign tumors of the breast, colon, and stomach show little ............... activity, whereas their malignant counterparts overexpress this enzyme
    type IV collagenase
  24. What is the ameboid migration?
    • Recent in vivo imaging experiments have shown that tumor cells can adopt a second mode of invasion, termed ameboid migration.
    • In this type of migration the cell squeezes through spaces in the matrix instead of cutting its way through it. This ameboid migration is much quicker, and tumor cells seem to be able to use collagen fibers as high-speed railways in their travels.
  25. Why has the performance of MMP inhibitors in clinical trials been disappointing?
    Tumor cells, in vitro at least, seem to be able to switch between the two forms of migration (degradation of ECM and ameboid migration)
  26. The second step in invasion is .....................................
    local degradation of the basement membrane and interstitial connective tissue
  27. The third step in invasion involves ......................................
    changes in attachment of tumor cells to ECM proteins
  28. How do tumors produce changes in attachment of tumor cells to ECM proteins?
    • Normal epithelial cells have receptors, such as integrins, for basement membrane laminin and collagens that are polarized at their basal surface; these receptors help to maintain the cells in a resting, differentiated state.
    • Loss of adhesion in normal cells leads to induction of apoptosis, while, not surprisingly, tumor cells are resistant to this form of cell death.
    • Additionally, the matrix itself is modified in ways that promote invasion and metastasis.
    • For example, cleavage of the basement membrane proteins collagen IV and laminin by MMP2 or MMP9 generates novel sites that bind to receptors on tumor cells and stimulate migration.
  29. .................is the final step of invasion
    Locomotion
  30. What happens in locomotion?
    • Locomotion is the final step of invasion, propelling tumor cells through the degraded basement membranes and zones of matrix proteolysis.
    • Migration is a complex, multistep process that involves many families of receptors and signaling proteins that eventually impinge on the actin cytoskeleton.
    • Cells must attach to the matrix at the leading edge, detach from the matrix at the trailing edge, and contract the actin cytoskeleton to ratchet forward.
    • Such movement seems to be potentiated and directed by tumor cell–derived cytokines, such as autocrine motility factors
    • In addition, cleavage products of matrix components (e.g., collagen, laminin) and some growth factors (e.g., IGFs I and II) have chemotactic activity for tumor cells. Furthermore, proteolytic cleavage liberates growth factors bound to matrix molecules.
    • Stromal cells also produce paracrine effectors of cell motility, such as hepatocyte growth factor–scatter factor, which bind to receptors on tumor cells. Concentrations of hepatocyte growth factor–scatter factor are elevated at the advancing edges of the highly invasive brain tumor glioblastoma multiforme, supporting their role in motility.
  31. Concentrations of .......................... are elevated at the advancing edges of the highly invasive brain tumor glioblastoma multiforme, supporting their role in motility.
    hepatocyte growth factor–scatter factor
  32. What are the factors involved in each step of invasion?
    • Dissociation of cells from one another-->E-Cadherin and catenin
    • Local degradation of the basement membrane and interstitial connective tissue--> MMPs, cathepsin D, and urokinase plasminogen activator /ameboid migration
    • Changes in attachment of tumor cells to ECM proteins-->cleavage of collagen IV and laminin by MMP2 or MMP9 generates novel binding site
    • Locomotion --> tumor cell–derived cytokines, such as autocrine motility factors, cleavage products of matrix components (e.g., collagen, laminin) and some growth factors (e.g., IGFs I and II) , hepatocyte growth factor–scatter factor (by stromal cell)
  33. True or false: tumor-associated fibroblasts exhibit altered expression of genes that encode ECM molecules, proteases, protease inhibitors, and various growth factors
    True
  34. How might the tumors in vasculature be destroyed?
    • Mechanical shear stress,
    • Apoptosis stimulated by loss of adhesion, (which has been termed anoikis),
    • Innate and adaptive immune defenses
  35. What is favored by homotypic adhesions among tumor cells as well as heterotypic adhesion between tumor cells and blood cells, particularly platelets ?
    aggregating of tumor cells in clumps
  36. Tumors like to adhere to which type of blood cells?
    Platelets
  37. What happens to the tumors when in the circulation?
    • Within the circulation, tumor cells tend to aggregate in clumps. This is favored by homotypic adhesions among tumor cells as well as heterotypic adhesion between tumor cells and blood cells, particularly platelets.
    • Formation of platelet-tumor aggregates may enhance tumor cell survival and implantability.
    • Tumor cells may also bind and activate coagulation factors, resulting in the formation of emboli. Arrest and extravasation of tumor emboli at distant sites involves adhesion to the endothelium, followed by egress through the basement membrane. Involved in these processes are adhesion molecules (integrins, laminin receptors) and proteolytic enzymes. 
    • Of particular interest is the CD44 adhesion molecule, which is expressed on normal T lymphocytes and is used by these cells to migrate to selective sites in the lymphoid tissue. Such migration is accomplished by the binding of CD44 to hyaluronate on high endothelial venules, and overexpression of CD44 may favor metastatic spread.
    • At the new site, tumor cells must proliferate, develop a vascular supply, and evade the host defenses
  38. What is the role of CD44 in metastasis?
    • CD44 adhesion molecule is expressed on normal T lymphocytes and is used by these cells to migrate to selective sites in the lymphoid tissue.
    • Such migration is accomplished by the binding of CD44 to hyaluronate on high endothelial venules, and overexpression of CD44 may favor metastatic spread.
  39. The site at which circulating tumor cells leave the capillaries to form secondary deposits is related, in part, to the ..........................
    anatomic location of the primary tumor, with most metastases occurring in the first capillary bed available to the tumor
  40. Which metastasis are not explained by anatomic site of the tumor?
    • prostatic carcinoma preferentially spreads to bone
    • bronchogenic carcinomas tend to involve the adrenals and the brain
    • neuroblastomas spread to the liver and bones
  41. How can organ tropisms be explained?
    • Because the first step in extravasation is adhesion to the endothelium, tumor cells may have adhesion molecules whose ligands are expressed preferentially on the endothelial cells of the target organ.
    • Chemokines have an important role in determining the target tissues for metastasis. For instance, some breast cancer cells express the chemokine receptors CXCR4 and CCR7. The chemokines that bind to these receptors are highly expressed in tissues to which breast cancers commonly metastasize. Blockage of the interaction between CXCR4 and its receptor decreases breast cancer metastasis to lymph nodes and lungs. Some target organs may liberate chemoattractants that recruit tumor cells to the site. Examples include IGFs I and II.
    • In some cases, the target tissue may be a nonpermissive environment—unfavorable soil, so to speak, for the growth of tumor seedlings. For example, though well vascularized, skeletal muscles are rarely the site of metastases.
  42. True or false: endothelial cells of the vascular beds of various tissues differ in their expression of ligands for adhesion molecules
    True
  43. True or false: tumor cells are quite inefficient in colonizing distant organs
    True
  44. What is dormancy?
    • prolonged survival of micrometastases without progression
    • is well described in melanoma and in breast and prostate cancer
  45. What is the molecular mechanisms of colonization?
    • Tumor cells secrete cytokines, growth factors, and ECM molecules that act on the resident stromal cells, which in turn make the metastatic site habitable for the cancer cell.  
    • For example, breast cancer metastases to bone are osteolytic because of the activation of osteoclasts in the metastatic site. Breast cancer cells secrete parathyroid hormone–related protein (PTHRP), which stimulates osteoblasts to make RANK ligand (RANKL).
    • RANKL then activates osteoclasts, which degrade the bone matrix and release growth factors embedded within it, like IGF and TGF-β.
  46. What is the The clonal evolution model of metastasis?
    The clonal evolution model suggest that, as mutations accumulate in genetically unstable cancer cells and the tumor become heterogeneous  a subset of tumor cell subclones develop the right combination of gene products to complete all the steps involved in metastasis. Thus, metastatic subclones result from clonal evolution, and it is only the rare cell that acquires all the necessary genetic alterations and can complete all the steps
  47. Why the recent experiments, in which gene expression profiles of primary tumors and metastatic deposits have been compared, challenge clonal evolution model?
    • For example, a subset of breast cancers has a gene expression signature similar to that found in metastases, although no clinical evidence for metastasis is apparent.
    • In these tumors it seems that most if not all cells develop a predilection for metastatic spread during early stages of carcinogenesis. Metastases, according to this view, are not dependent on the stochastic generation of metastatic subclones.
    • The alternative hypothesis suggested by these data is that metastasis is the result of multiple abnormalities that occur in many, perhaps most, cells of a primary tumor, and perhaps early in the development of the tumor
    • Such abnormalities give most cells within the tumor a general predisposition for metastasis, often called the “metastasis signature.”  This signature may involve not only properties intrinsic to the cancer cells but also the characteristics of their microenvironment, such as the components of the stroma, the presence of infiltrating immune cells, and angiogenesis
  48. What are the two other metastatic hypothesis in addition to clonal evolution and metastatic signature?
    • A third hypothesis suggests that background genetic variation, and the resulting variation in gene expression, in the human population contributes to the generation of metastases. In mouse models, cancers induced with the same oncogenic mutations can have very different metastatic outcomes depending on the strain (i.e., background genetics) of the mouse used. Even very strong oncogenes can be significantly affected by background genetics.
    • The fourth hypothesis is a corollary of the tumor stem cell hypothesis, which suggests that if tumors derive from rare tumor stem cells, metastases require the spread of the tumor stem cells themselves.
  49. What are the four hypotheses of metastasis?
    •  A, Metastasis is caused by rare variant clones that develop in the primary tumor; B, Metastasis is caused by the gene expression pattern of most cells of the primary tumor, referred to as a metastatic signature; C, A combination of A and B, in which metastatic variants appear in a tumor with a metastatic gene signature; D, Metastasis development is greatly influenced by the tumor stroma, which may regulate angiogenesis, local invasiveness, and resistance to immune elimination, allowing cells of the primary tumor, as in C, to become metastatic
    • Also SC hypothesis and background genetic variation
  50. True or false: genes that function as “metastasis oncogenes” or “metastatic suppressors” are rare
    True
  51. Which genes might particularly act as “metastasis oncogenes” or “metastatic suppressors” ?
    • MiRNA --> suppressor or oncogene
    • SNAIL and TWIST, which encode transcription factors whose primary function is to promote a process called epithelial-to mesenchymal transition (EMT)--> oncogene
  52. What is epithelial-to mesenchymal transition (EMT)?
    • Among candidates for metastasis oncogenes are SNAIL and TWIST, which encode transcription factors whose primary function is to promote a process called epithelial-to mesenchymal transition (EMT).
    • In EMT, carcinoma cells down-regulate certain epithelial markers (e.g., E-cadherin) and up-regulate certain mesenchymal markers (e.g., vimentin and smooth muscle actin). These changes are believed to favor the development of a promigratory phenotype that is essential for metastasis. Loss of E-cadherin expression seems to be a key event in EMT, and SNAIL and TWIST are transcriptional repressors that down-regulate E-cadherin expression. EMT has been documented mainly in breast cancers
  53. ...................... expression seems to be a key event in EMT
    Loss of E-cadherin
  54. ............ are transcriptional repressors that down-regulate E-cadherin  promoting EMT
  55. True or False: genomic instability occurs when both copies of the DNA repair gene are lost
    • True 
    • (With some exceptions that haploinsufficiency occur)
  56. Defects in three types of DNA-repair systems—.......................................—contribute to different types of cancers
    • mismatch repair
    • nucleotide excision repair
    • recombination repair
  57. HNPCC syndrome, characterized by familial carcinomas of the colon affecting predominantly the cecum and proximal colon results from defects in genes involved in ..................
    DNA mismatch repair
  58. What is the function of mismatch repair genes?
    • When a strand of DNA is being replicated, these genes act as “spell checkers.”
    • For example, if there is an erroneous pairing of G with T rather than the normal A with T, the mismatch-repair genes correct the defect.
    • Without these “proofreaders,” errors gradually accumulate randomly in the genome, and some of these errors may involve proto-oncogenes and tumor suppressor genes.
    • One of the hallmarks of patients with mismatch-repair defects is microsatellite instability
  59. One of the hallmarks of patients with ..................... is microsatellite instability
    mismatch-repair defects
  60. What are microsatellites?
    • Microsatellites are tandem repeats of one to six nucleotides found throughout the genome.
    • In normal people the length of these microsatellites remains constant.
    • However, in people with HNPCC, these satellites are unstable and increase or decrease in length in tumor cells, creating alleles not found in normal cells of the same patient
  61. What are the DNA mismatch-repair genes involved in HNPCC?
    germline mutations in the MSH2 (2p16) and MLH1 (3p21) genes each account for approximately 30% of cases
  62. What is the similarities and differences between mismatch repair genes and tumor suppressor and oncogenes?
    • Each affected individual inherits one defective copy of a DNA mismatch-repair gene and acquires the second hit in colonic epithelial cells.
    • Thus, DNA-repair genes behave like tumor suppressor genes in their mode of inheritance, but in contrast to tumor suppressor genes (and oncogenes), they affect cell growth only indirectly—by allowing mutations in other genes during the process of normal cell division. 
  63. What are the features of Xeroderma Pigmentosum?
    • Increased risk for the development of cancers of the skin particularly following exposure to the UV light contained in sun rays.
    • UV radiation causes cross-linking of pyrimidine residues, preventing normal DNA replication. Such DNA damage is repaired by the nucleotide excision repair system.
    • Several proteins are involved in nucleotide excision repair, and an inherited loss of any one can give rise to xeroderma pigmentosum.
  64. What are the diseases characterized by Defects in DNA Repair by Homologous Recombination?
    • A group of AR disorders comprising Bloom syndrome, ataxia-telangiectasia, and Fanconi anemia is characterized by hypersensitivity to other DNA-damaging agents, such as ionizing radiation (Bloom syndrome and ataxia-telangiectasia), or DNA cross-linking agents, such as many chemotherapeutic agents (Fanconi anemia).
    • Their phenotype is complex and includes, in addition to predisposition to cancer, features such as neural symptoms (ataxia-telangiectasia), bone marrow aplasia (Fanconi anemia), and developmental defects (Bloom syndrome)
  65. hypersensitivity to ionizing radiation is characteristic of.........
    • AT
    • Bloom
  66. hypersensitivity to cross-linking agents is characteristic of.........
    Fanconi anemia
  67. What is the genetic defect in bloom syndrome?
    Persons with Bloom syndrome have a predisposition to a very broad spectrum of tumors. The defective gene is located on chromosome 15 and encodes a helicase that participates in DNA repair by homologous recombination
  68. ............, which is mutated in some individuals with familial breast cancer, is also mutated in a subset of persons with Fanconi anemia.
    BRCA2
  69. Risk of which cancers are increased in patients with BRCA1 or 2 mutation?
    • Mutations in two genes, BRCA1 (chromosome 17q) and BRCA2 (chromosome 13q), account for 25% of cases of familial breast cancer.
    • In addition to breast cancer, women with BRCA1 mutations have a substantially higher risk of epithelial ovarian cancers, and men have a slightly higher risk of prostate cancer.
    • Likewise, mutations in the BRCA2 gene increase the risk of breast cancer in both men and women as well as cancer of the ovary, prostate, pancreas, bile ducts, stomach, and melanocytes
  70. What is the function of BRCA1 and 2?
    • Cells that lack these genes develop chromosomal breaks and severe aneuploidy.
    • Indeed, both BRCA1and BRCA2 have been shown to associate with a variety of proteins involved in the homologous recombination repair pathway.
    • The Fanconi anemia proteins and the BRCA proteins form a DNA-damage response network whose purpose is to resolve and repair intrastrand and interstrand DNA cross-links induced by chemical cross-linking agents.
    • Failure to resolve these cross-links before separation of the two strands would lead to chromosome breakage and exposed chromosome ends.
    • Generation of such ends would, as with short telomeres, lead to the activation of the salvage nonhomologous end joining pathway, formation of dicentric chromosomes, bridge-fusion-breakage cycles, and massive aneuploidy.
    • Similar to other tumor suppressor genes, both copies of BRCA1 and BRCA2 must be inactivated for cancer to develop.
  71. True or false: Although linkage of BRCA1 and BRCA2 to familial breast cancers is established, these genes are rarely inactivated in sporadic cases of breast cancer.
    True
  72. What are some examples of cross-talk between tumor and ECM?
    • cleavage of matrix components such as type IV collagen releases angiogenic factors (VEGF), and enzymatic degradation of laminin-5 by MMP2 reveals a cryptic proteolytic fragment that favors cancer cell motility.
    • The ECM also stores growth factors in inactive forms, which are released by active matrix proteases. Such factors include PDGF, TGF-β, and bFGF, which in turn affect the growth of tumor cells in a paracrine manner.
  73. What is the interaction of inflammation and cancer cells?
    • Expression of pro-survival and pro-proliferation cytokines by immune cells, not only promote the development of cancer, but also promote survival and progression of tumor cells.
    • Macrophages infiltrating the tumor can be induced by the tumor cells to secrete factors that promote metastasis.
  74. What is the role of fibroblasts in tumor?
    • Fibroblasts secrete the matrix that results in the desmoplastic response to tumors.
    • Interestingly, in vitro experiments that altered the stiffness of the matrix alone could change the aggressiveness of a cancer cell line. Thus, the desmoplastic response to cancer may be stimulated by the cancer cells and may promote their growth.
    • Stroma can drive genetic changes that promote carcinogenesis.
  75. What is THE WARBURG EFFECT or aerobic glycolysis?
    Even in the presence of ample oxygen, cancer cells shift their glucose metabolism away from the oxygen hungry, but efficient, mitochondria to glycolysis
  76. the “glucose-hunger” of tumors is used to visualize tumors via.................
    PET
  77. What are the mechanisms of Warburg effect?
    • Altered metabolism confers a growth advantage in the hypoxic tumor microenvironment. Although angiogenesis generates increased vasculature, the vessels are poorly formed, and tumors are still relatively hypoxic compared to normal tissues. Indeed, the activation of HIF1α by hypoxia not only stimulates angiogenesis, but also increases the expression of numerous metabolic enzymes in the glycolytic pathway as well as downregulates genes involved in oxidative phosphorylation. Decreased demand by individual tumor cells increases the oxygen supply, thus increasing the number of tumor cells that can be supported by the vasculature and increasing the size of the tumor
    • Warburg effect refers to aerobic glycolysis; glycolysis that occurs in the face of adequate oxygen for oxidative phosphorylation. Thus, the changes that promote the switch in metabolism during hypoxia must become fixed in the tumor cell. It may be that continuous rounds of hypoxia followed by normoxia, as is frequently seen in tumors, select for tumor cells that constitutively upregulate glycolysis. 
    • Mutations in oncogenes and tumor suppressors that favor growth, such as RAS, p53 and PTEN, also stimulate metabolic changes in the cell.
    • In addition to doubling its DNA content prior to division, an actively dividing cell (whether normal or transformed) must also double all of its other components, including membranes, proteins, and organelles. This task requires increased uptake of nutrients, particularly glucose (which produces the energy needed for biosynthesis of these components) and amino acids (which provide the building blocks used for protein synthesis) as well as increased synthesis of the necessary building blocks. Halting the breakdown of glucose at pyruvate allows these carbons to be shunted to anabolic pathways, such as lipid and nucleotide production; additionally, tumor cells are able to shunt glutamine into both the glycolytic as well as anabolic pathways.  Thus, the metabolic changes that tumor cells undergo increase their ability to synthesize the building blocks they need for cell division. Indeed, alterations in signaling pathways involved in cancer also stimulate the uptake of glucose and other nutrients, favor glycolysis over oxidative phosphorylation, and increase anabolic pathways in the cell.
    • Normally, growth factors stimulate glucose and amino acid uptake through the PI3K/AKT/mTOR pathway, which is downstream of receptor tyrosine kinases and other growth factor receptors; in tumors, these signals are cell autonomous. Thus, mutation of tumor suppressors and oncogenes not only leads to constitutive activation of pathways that favor survival and proliferation, but they also make glycolysis and anabolic biosynthesis a permanent fixture of the tumor cell.
  78. What are the metabolic changes in tumor?
    • uptake of glucose and other nutrients
    • favor glycolysis over oxidative phosphorylation,
    • increase anabolic pathways in the cell
  79. What is the function of LKB1 in metabolism?
    • LKB1, a tumor suppressor gene encoding a threonine kinase that is mutated in Peutz-Jegher syndrome , which is associated with benign and malignant epithelial proliferations of the gastrointestinal tract.
    • At least one aspect of LKB1's tumor suppressive activity is mediated through its ability to activate AMP-dependent protein kinase (AMPK), a conserved sensor of cellular energy status that is an important negative regulator of mTOR.
    • Thus LKB1 suppresses tumor formation, at least in part, by putting the brakes on anabolic metabolism
  80. TSC1 and TSC2  .................regulate mTOR
    negatively
  81. What is the importance of autophagy in tumors?
    • One adaptive response of normal cells to oxygen and glucose deprivation isautophagy, a state in which cells arrest their growth and cannibalize their own organelles, proteins, and membranes as carbon sources for energy production. If this adaptation fails, the cells die.
    • Tumor cells often seem to be able to grow under marginal environmental conditions without triggering autophagy, suggesting that the pathways that induce autophagy are deranged. In keeping with this, several genes that promote autophagy are tumor suppressors, most notable PTEN (a negative regulator of the PI3K/AKT pathway), which is mutated or epigenetically silenced in a wide variety of human cancers
    • Under conditions of severe nutrient deprivation tumor cells may use autophagy to become “dormant,” a state of metabolic hibernation that allows cells to survive hard times for long periods. Such cells are believed to be resistant to therapies that kill actively dividing cells, and could therefore be responsible for therapeutic failures.
  82. What is an important example of a gene that promote autophagy?
    PTEN
  83. True or False: Although changes in chromosome number (aneuploidy) and structure are generally considered to be late phenomena in cancer progression, it has been suggested that aneuploidy and chromosomal instability may be the initiating events in tumor growth.
    True
  84. which genetic features may be the initiating events in tumor growth?
    aneuploidy and chromosomal instability
  85. What are two types of chromosomal rearrangements can activate proto-oncogenes?
    translocations and inversions
  86. How can translocations active proto-oncogene?
    • In lymphoid tumors specific translocations result in overexpression of proto-oncogenes by swapping their regulatory elements with those of another gene.  
    • In many hematopoietic tumors, sarcomas, and certain carcinomas, the translocations allow normally unrelated sequences from two different chromosomes to recombine and form hybrid fusion genes that encode chimeric proteins that variously promote growth and survival, or enhance self-renewal and block differentiation
  87. What are the translocation in Burkitt lymphoma?
    • Overexpression of a proto-oncogene caused by translocation.
    • All such tumors carry one of three translocations, each involving chromosome 8q24 (MYC gene), as well as one of the three immunoglobulin gene–carrying chromosomes.
    • At its normal locus, MYC is tightly controlled, and is most highly expressed in actively dividing cells.
    • In Burkitt lymphoma the most common form of translocation results in the movement of the MYC-containing segment of chromosome 8 to chromosome 14q32, placing it close to the IGH gene.
    • In most cases the translocation causes mutation or loss of the regulatory sequences of the MYC gene, replacing them with the control regions of the IGH locus, which is highly expressed in B-cell precursors. As the coding sequences remain intact, the gene is constitutively expressed at high levels. The invariable presence of the translocated MYC gene in Burkitt lymphomas attests to the importance of MYC overactivity in the pathogenesis of this tumor
  88. ................... is required for pathogenicity of Burkitt lymphoma
    MYC overactivity
  89. Most affected oncogenes in translocation of lymphoma are ...............
    Transcription factors
  90. What are the important translocations in mantle cell lymphoma and follicular lymphoma?
    • Mantle cell lymphoma the cyclin D1 gene (CCND1) on chromosome 11q13 is overexpressed by juxtaposition to the IGH locus on 14q32.
    • In follicular lymphomas, a t(14;18)(q32;q21) translocation, the most common translocation in lymphoid malignancies, causes activation of the BCL2 gene
  91. What are the features of philadelphia chromosome?
    • The Philadelphia chromosome, characteristic of CML and a subset of acute lymphoblastic leukemias, provides the prototypic example of an oncogene formed by fusion of two separate genes.
    • In these cases, a reciprocal translocation between chromosomes 9 and 22 relocates a truncated portion of the proto-oncogene c-ABL (from chromosome 9) to the BCR (breakpoint cluster region) on chromosome 22.
    • The hybrid fusion gene BCR-ABL encodes a chimeric protein that has constitutive tyrosine kinase activity.
    • Although the translocations are cytogenetically identical in CML and acute lymphoblastic leukemias, they usually differ at the molecular level.
    • In most cases of CML the chimeric protein has a molecular weight of 210 kD, whereas in the more aggressive acute leukemias a 190-kD BCR-ABL fusion protein is typically formed
  92. What are some important translocations?
    • ABL (9q)–BCR (22) (9;22): CML
    • ATF1 (12)–EWS (22) (12;22): Malignant melanoma of soft parts
    • BCL1 (11)–IgH (14) (11;14): Mantle cell lymphoma
    • BCL2 (18)–IgH (14) (14;18): Follicular lymphoma
    • FLI1 (11)–EWS (22) (11;22): Ewing's sarcoma
    • LCK (1)–TCRB (7) (1;7): T cell ALL
    • MYC (8q)–IgH (14q) (8;14): Burkitt's lymphoma, B cell acute lymphocytic leukemia
    • PAX3 (2)–FKHR/ALV (13) (2;13): Alveolar rhabdomyosarcoma
    • PAX7 (1)–KHR/ALV(13) (1;13): Alveolar rhabdomyosarcoma
    • RET (10)–PKAR1A (17) (10;17): Thyroid carcinoma
    • TAL1(1)–TCTA (3) (1;3): Acute T cell leukemia
    • TRK (1) TPM3 (1) Inv1(q23;q31): Colon carcinoma
    • WT1 (11)–EWS (22) (11;22): Desmoplastic small round cell tumor
    • HOX (11)-TCRA(14) (10;14): T cell ALL
    • TMPRSS2 (21q) with other genes (ERG or ETV1) -->(21:21)(21:17)(21:7) Prostatic adenocarcinoma
    • PML(15q) RARA(17q) t(15q:17q) AML M3
  93. What are some TF seen in fusion genes in tumors?
    • The MLL gene on 11q23, a component of a chromatin-remodeling complex (many)
    • Ewing sarcoma (EWSR1) gene at 22q12. In Ewing sarcoma/PNET, the EWSR1 gene fuses with the FLI1 gene (a member of the ETS TF family)
    • Translocation involving an androgen-regulated gene, TMPRSS2(21q22), and one of three ETS family transcription factors (ERG [21q22], ETV1 [7p22.2], or ETV4 [17q21]) in 50% prostate adenocarcinomas.
  94. What is the function of translocation involving TMPRSS2 in prostate cancer?
    • a translocation involving an androgen-regulated gene, TMPRSS2(21q22), and one of three ETS family transcription factors (ERG [21q22], ETV1 [7p22.2], or ETV4 [17q21]) was found to be present in 50% or more prostate adenocarcinomas.
    • Development of this translocation seems to occur early in carcinogenesis, in that it is also present in high-grade prostatic intraepithelial neoplasia, a precursor lesion.
    • It removes the ETS family gene from its normal control region and fuses it to the androgen-regulated TMPRSS2. Thus, the ETS family transcription factor is inappropriately expressed in prostate cells
  95. What is the most common structural abnormality in tumor?
    Translocation
  96. What is the second mc structural abnormality in tumors?
    Deletions
  97. Compared with translocations, deletions are more common in ......................................................
    nonhematopoietic solid tumors
  98. deletions involving chromosome 13q14, the site of the ........., are associated with .......................
    RB gene/retinoblastoma
  99. Deletions of ............................ have all been noted in colorectal cancers; these regions harbor three tumor suppressor genes
    17p, 5q, and 18q
  100. Deletion of 3p is extremely common in ..............................
    small cell lung cancer

What would you like to do?

Home > Flashcards > Print Preview